1. The Predictive Value of Pretreatment Lactate Dehydrogenase and Derived Neutrophil-to-Lymphocyte Ratio in Advanced Non-Small Cell Lung Cancer Patients Treated With PD-1/PD-L1 Inhibitors: A Meta-Analysis
   Qianning Zhang et al, 2022, Frontiers in Oncology CrossRef
2. PD-1/PD-L1 immune-checkpoint blockade induces immune effector cell modulation in metastatic non-small cell lung cancer patients: A single-cell flow cytometry approach
   Antonella Fameli et al, 2022, Frontiers in Oncology CrossRef
3. Preexisting autoantibodies as predictor of immune related adverse events (irAEs) for advanced solid tumors treated with immune checkpoint inhibitors (ICIs)
   A Daban et al, 2023, OncoImmunology CrossRef
4. Prediction of Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors With a Panel of Autoantibodies: Protocol of a Multicenter, Prospective, Observational Cohort Study
   Iñigo Les et al, 2022, Frontiers in Pharmacology CrossRef
5. The presence of autoantibodies is associated with improved overall survival in lung cancer patients
   Keying Jing et al, 2023, Frontiers in Oncology CrossRef
6. Safety and Efficacy of PD-1/PD-L1 Inhibitors in Cancer Patients With Preexisting Autoantibodies
   Hui Tang et al, 2022, Frontiers in Immunology CrossRef
7. Antinuclear antibodies may predict the development of immune-related adverse events in asymptomatic patients treated with immune checkpoint inhibitors: results from a single-center cohort
   Fulvia Ceccarelli et al, 2024, Clinical and Experimental Medicine CrossRef
8. Real-world effectiveness of immunotherapies in pre-treated, advanced non-small cell lung cancer Patients: A systematic literature review
   Ariadna Juarez-Garcia et al, 2022, Lung Cancer CrossRef
9. Distinctive Role of the Systemic Inflammatory Profile in Non-Small-Cell Lung Cancer Younger and Elderly Patients Treated with a PD-1 Immune Checkpoint Blockade: A Real-World Retrospective Multi-Institutional Analysis
   Valerio Nardone et al, 2021, Life CrossRef
10. Association between Changes in the Patterns of Antinuclear Autoantibodies during Immune Checkpoint Inhibition Therapy and the Development of Severe Immune Related Adverse Events
    Leticia Alserawan et al, 2022, International Journal of Molecular Sciences CrossRef
11. Role of B cells in immune‐related adverse events following checkpoint blockade
    Kavita M. Dhodapkar et al, 2023, Immunological Reviews CrossRef
12. B cell clonality in cancer
    E.A. Bryushkova et al, 2024, Seminars in Immunology CrossRef
13. Circulating predictive markers of immune checkpoint inhibitors in non-small cell lung cancer
    A. A. Musaelyan et al, 2021, Advances in Molecular Oncology CrossRef
14. Antibody Diversity in Cancer: Translational Implications and Beyond
    Raghuram Reddy et al, 2022, Vaccines CrossRef
15. Efficacy and Feasibility of Programmed Death-1/Programmed Death Ligand-1 Blockade Therapy in Non-Small Cell Lung Cancer Patients With High Antinuclear Antibody Titers
    Atsuto Mouri et al, 2021, Frontiers in Oncology CrossRef
16. Inflammatory Markers and Procalcitonin Predict the Outcome of Metastatic Non-Small-Cell-Lung-Cancer Patients Receiving PD-1/PD-L1 Immune-Checkpoint Blockade
    Valerio Nardone et al, 2021, Frontiers in Oncology CrossRef
17. Case Report: Immune checkpoint inhibitor–induced multiorgan vasculitis successfully treated with rituximab
    Sehrish Qureshi et al, 2023, Frontiers in Nephrology CrossRef